Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) have been assigned an average rating of “Buy” from the sixteen analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $83.68.

A number of research analysts have recently commented on ONCE shares. Stifel Nicolaus restated a “buy” rating and set a $76.00 price target on shares of Spark Therapeutics in a research report on Monday, April 10th. William Blair started coverage on shares of Spark Therapeutics in a research report on Wednesday, June 28th. They set an “outperform” rating for the company. ValuEngine upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 9th. Finally, Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th.

COPYRIGHT VIOLATION WARNING: “Spark Therapeutics, Inc. (ONCE) Given Average Rating of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/spark-therapeutics-inc-once-given-average-rating-of-buy-by-analysts.html.

In other news, CEO Jeffrey D. Marrazzo sold 9,331 shares of the company’s stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $65.00, for a total transaction of $606,515.00. Following the completion of the transaction, the chief executive officer now directly owns 230,534 shares of the company’s stock, valued at $14,984,710. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen W. Webster sold 7,663 shares of the company’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $60.00, for a total transaction of $459,780.00. Following the transaction, the chief financial officer now directly owns 10,163 shares of the company’s stock, valued at $609,780. The disclosure for this sale can be found here. Insiders sold 314,310 shares of company stock valued at $21,866,838 over the last three months. 7.30% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. increased its position in shares of Spark Therapeutics by 0.3% in the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock valued at $2,067,000 after buying an additional 122 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of Spark Therapeutics by 4.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 8,204 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 320 shares during the period. Nationwide Fund Advisors increased its position in shares of Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock valued at $923,000 after buying an additional 414 shares during the period. KCG Holdings Inc. increased its position in shares of Spark Therapeutics by 9.4% in the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 538 shares during the period. Finally, Teachers Advisors LLC increased its position in shares of Spark Therapeutics by 1.9% in the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after buying an additional 650 shares during the period. 88.95% of the stock is owned by hedge funds and other institutional investors.

Spark Therapeutics (ONCE) traded up 0.19% during trading on Tuesday, hitting $78.78. The stock had a trading volume of 823,813 shares. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $79.63. The firm has a 50 day moving average price of $63.15 and a 200-day moving average price of $58.70. The firm’s market capitalization is $2.44 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter last year, the firm earned ($1.04) earnings per share. On average, equities research analysts expect that Spark Therapeutics will post ($7.35) EPS for the current year.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.